3-(4-Methylsulfanyl-phenyl)-3-oxo-propionic acid | 592529-06-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(4-Methylsulfanyl-phenyl)-3-oxo-propionic acid
• 英文别名: 3-(4-Methylsulfanylphenyl)-3-oxopropanoic acid
• CAS: 592529-06-1
• 化学式: C₁₀H₁₀O₃S
• 分子量: 210.254
• InChiKey: KDNYCHXTYBFFTF-UHFFFAOYSA-N

物化性质

• 沸点：
  434.2±30.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  79.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-Methylsulfanyl-phenyl)-3-oxo-propionic acid 在 氢氧化钾 、 phosphate buffer 、 氢溴酸 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 62.0h， 生成 6-(4-hydroxyphenyl)-7-(4-methylsulfanylphenyl)-2,3,8,8a-tetrahydro-1H-indolizin-5-one
  参考文献：
  名称：

  Novel 6,7-diphenyl-2,3,8,8a-tetrahydro-1H-indolizin-5-one analogues as cytotoxic agents

  摘要：

  A series of 6,7-diphenyl-2,3,8,8a-tetrahydro-1H-indolizin-5-one analogues were synthesized and evaluated for cytotoxic activity against eight human cancer cell lines. Compounds 18, 21, 28, 29, 30 and 31 showed cytotoxic activity with GI(50) values in the range of 2.1-8.1 muM concentration. Among these, compounds 21 and 28 exhibited good pharmacokinetic properties. These compounds were further evaluated for their in vivo efficacy in modified hollow fibre assay (HFA). (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00263-4
• 作为产物：
  描述：

  methyl 3-[4-(methylsulfanyl)phenyl]-3-oxopropanoate 在 氢氧化钾 作用下， 反应 24.0h， 生成 3-(4-Methylsulfanyl-phenyl)-3-oxo-propionic acid
  参考文献：
  名称：

  Novel 6,7-diphenyl-2,3,8,8a-tetrahydro-1H-indolizin-5-one analogues as cytotoxic agents

  摘要：

  A series of 6,7-diphenyl-2,3,8,8a-tetrahydro-1H-indolizin-5-one analogues were synthesized and evaluated for cytotoxic activity against eight human cancer cell lines. Compounds 18, 21, 28, 29, 30 and 31 showed cytotoxic activity with GI(50) values in the range of 2.1-8.1 muM concentration. Among these, compounds 21 and 28 exhibited good pharmacokinetic properties. These compounds were further evaluated for their in vivo efficacy in modified hollow fibre assay (HFA). (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00263-4

文献信息

• Decarboxylative fluorination of β-Ketoacids with N-fluorobenzenesulfonimide (NFSI) for the synthesis of α-fluoroketones: Substrate scope and mechanistic investigation
  作者：Rui Zhang、Chuanfa Ni、Zhengbiao He、Jinbo Hu

  DOI：10.1016/j.jfluchem.2017.08.010

  日期：2017.11

  Cesium carbonate (Cs2CO3)-mediated decarboxylative fluorination of β-ketoacids using NFSI in the MeCN/H2O mixed solvent system affords α-fluoroketones with a broad scope. Both electron-rich and electron-deficient α-non-substituted β-ketoacids are amenable to this protocol. The mechanistic study indicates that the reaction proceeds through electrophilic fluorination followed by decarboxylation, which

  在MeCN / H 2 O混合溶剂体系中，使用NFSI进行碳酸铯（Cs 2 CO 3）介导的β-酮酸的脱羧氟化反应，可以得到范围很广的α-氟代酮。富含电子的和缺乏电子的α-非取代的β-酮酸均适用于该方案。机理研究表明，反应是通过亲电氟化反应继之以脱羧反应进行的，这不同于普通羧酸的脱羧氟化反应。
• Novel pyrimidinedione derivatives
  申请人：ORCHID CHEMICALS & PHARMACEUTICALS LIMITED

  公开号：US20040009975A1

  公开（公告）日：2004-01-15

  Pyrimidinedione derivatives of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them are useful for the treatment of inflammation and immunological diseases. 1

  式(I)的嘧啶二酮衍生物、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、水合物、溶剂化物、药学上可接受的盐以及含有它们的药学上可接受的组合物，对于治疗炎症和免疫性疾病是有用的。
• SALTS OF PAROXETINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1091958A1

  公开（公告）日：2001-04-18
• US7399760B2
  申请人：——

  公开号：US7399760B2

  公开（公告）日：2008-07-15
• [EN] SALTS OF PAROXETINE<br/>[FR] SELS DE PAROXETINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2000001692A1

  公开（公告）日：2000-01-13

  Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.